XB-2203 is under clinical development by XBiotech and currently in Phase I for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase I drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XB-2203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XB-2203 overview
Monoclonal antibody is under development for the treatment of Clostridium difficile infections. It is administered through oral route. The drug candidate is developed based on true human antibody technology that utilizes antibodies that are naturally occurring in the body and helps in treating patients infected by the virus.
XBiotech overview
XBiotech is biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.
For a complete picture of XB-2203’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
